Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs

Dermatologic Surgery

Volumn 32, Issue 6, 2006, Pages 804-808

  Treacy, Patrick J ^a   Goldberg, David J ^b,c,d  

^a Department of Medical Aesthetics   (Ireland)

^b Skin Laser and Surgery Specialists of NY and NJ   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Skin Laser and Surgery Specialists of NY/NJ   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOPOLYMER; IMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; ESTHETICS; FACE; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SAFETY; SWELLING; TREATMENT OUTCOME;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; BIOPOLYMERS; COSMETIC TECHNIQUES; FACE; FEMALE; FOLLOW-UP STUDIES; HIV; HIV ANTIBODIES; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS; LACTIC ACID; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; POLYMERS; TREATMENT OUTCOME;

EID: 33744922936     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2006.32164.x     Document Type: Article

References (25)

1. Oette M Juretzko P Kroidl A, et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS 2002 16 : 413 7.
2. Sekhar RV Jahoor F White AC, et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002 283 : 332 7.
3. Guaraldi G Orlando G De Fazio D. Prospective, partially randomized, 24-week study to compare the efficacy and durability of different surgical techniques and interventions for the treatment of HIV-related facial lipoatrophy. Sixth Lipodystrophy Workshop (6th IWADRLH), Washington, Abstract 12. Antiviral Therapy 2004; 9:L9.
4. Mauss S Corzillius M Wolf E, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002 3 : 49 55.
5. Carr A Miller J Law M Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000 18 : 25 32.
6. Moyle G Lysakovo L Brown S, et al. A randomised, open-label study of immediate vs. delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV injection. HIV Med 2004 5 : 82 7.
7. Valantin MA Aubron-Olivier CA. Polylactic acid implants (New-Fill®) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003 17 : 2471 7.
8. Olenius M. The first clinical study using a new biodegradable implant for the treatment of lips, wrinkles, and folds. Aesthetic Plast Surg 1998 22 : 97 101.
9. Gogolewski S Jovanovic M Perren SM, et al. Tissue response and vivo degradation of selected polyhydroxyacids (PLA, PHB, PHB/VA). J Biomed Mater Res 1993 27 : 1135 48.
10. See information from the Bio-Alcamid website.
11. Friezel G. Psychological assessment of patients referred to a multidisciplinary lipodystrophy/metabolic clinic. Seventh Annual Conference of the British HIV Association. April, 2001, Abstract P15.
12. Duran S Saves M Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001 7 : 2441 4.
13. Pinski KS Roenigk HH Jr.. Autologous fat transplantation: long-term follow-up. J Dermatol Surg Oncol 1992 18 : 179 84.
14. Kaminer MS Omura NE. Autologous fat transplantation. Arch Dermatol 2001 137 : 812 4.
15. De Fazio D Orlando G Murri R, et al. Surgical and cosmetic treatments for fat abnormalities. Autologous fat transfer for treating facial wasting in HIV body fat redistribution syndrome, 10th Conference on Retroviruses and Opportunistic Infections, Boston, February, 10-14 2004, poster.
16. Lafaurie M Dolivo J Boulu D, et al. Treatment of HIV-associated lipoatrophy of the face with intradermal injections of polylactic acid. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, February 22-28, 2002 [abstract #704-T].
17. Jones DH Carruthers A Orentreich D, et al. Highly purified 1000 centistoke silicone oil for the treatment of HIV-associated facial lipoatrophy: an open pilot trial. Dermatol Surg 2004 30 : 1279 86.
18. Wilkie TF. Late development of granuloma after liquid silicone injections. Plast Reconstr Surg 1977 60 : 179 88.
19. Tang L Eaton JW. Inflammatory responses to biomaterials. Am J Clin Pathol 1995 103 : 466 71.
20. Lemperle G Romano JJ Busso M. Soft tissue augmentation with artecoll: 10-year history, indications, techniques, and complications. Dermatol Surg 2003 29 : 573 87.
21. Lombardi T Samson J Plantier F, et al. Orofacial granulomas after injection of cosmetic fillers. Histopathologic and clinical study of 11 cases. J Oral Pathol Med 2004 11 : 115 20.
22. Formigli L Zecchi S Protopapa C, et al. Bio-Alcamid: an electron electron microscopic study after skin implantation. Plas Reconstruc Surg 2004 113 : 1104 6.
23. Protopapa B, Sito P, Caporale D, and Cammarota SS. Bio-Alcamid™ in drug-induced lipodystrophy. J Cosm Laser Ther 2003 5 : 226 30.
24. Pacini A Ruggiero S Morucci B, et al. Bio-Alcamid™: a novelty for reconstructive and cosmetic surgery. Italian J Anat Embryol 2002 107 : 209 14.
25. Ascher B Bui P Halabi A. Fillers in Europe. In : Goldberg DJ, editor. Dermal Fillers. London : Taylor & Francis, 2006.